VERV Stock Price, Verve Therapeutics, Inc. Quote, Chart

Market Summary

USD6.66-0.08

Market Closed

-1.19%

VERV Stock Price

View Fullscreen

VERV RSI Chart

VERV Valuation

Market Cap

545.9M

Price/Earnings (Trailing)

-2.73

Price/Sales (Trailing)

46.43

EV/EBITDA

-1.85

Price/Free Cashflow

-3.44

VERV Price/Sales (Trailing)

VERV Profitability

EBT Margin

-1606.14%

Return on Equity

-33.37%

Return on Assets

-26.58%

Free Cashflow Yield

-29.09%

VERV Fundamentals

VERV Revenue

Revenue (TTM)

11.8M

Rev. Growth (Yr)

340.98%

Rev. Growth (Qtr)

65.03%

VERV Earnings

Earnings (TTM)

-200.1M

Earnings Growth (Yr)

-17.69%

Earnings Growth (Qtr)

-5.67%

Breaking Down VERV Revenue

Last 7 days

-17.5%

Last 30 days

-48.8%

Last 90 days

-44.2%

Trailing 12 Months

-58.7%

How does VERV drawdown profile look like?

VERV Financial Health

Current Ratio

17.24

VERV Investor Care

Shares Dilution (1Y)

32.79%

Diluted EPS (TTM)

-3.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.4M	6.8M	9.3M	11.8M
2022	0	0	0	1.9M
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Verve Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	nickerson joan	sold	-12,475	8.24	-1,514	chief administrative officer
Apr 01, 2024	nickerson joan	acquired	-	-	3,315	chief administrative officer
Dec 01, 2023	yeshwant krishna	bought	18,000,000	10.00	1,800,000	-
Nov 29, 2023	dorval allison	acquired	-	-	1,875	chief financial officer
Nov 29, 2023	dorval allison	sold	-6,343	11.45	-554	chief financial officer
Sep 18, 2023	adelman burt a	gifted	-	-	37,168	-
Sep 18, 2023	adelman burt a	gifted	-	-	-37,168	-
Aug 11, 2023	adelman burt a	gifted	-	-	266,258	-
Aug 11, 2023	adelman burt a	gifted	-	-	-266,258	-
Dec 14, 2022	bellinger andrew	acquired	103,320	2.87	36,000	cso & cmo

Which funds bought or sold VERV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 10, 2024	Green Alpha Advisors, LLC	added	11.51	19,421	331,203	0.24%
Apr 05, 2024	CWM, LLC	added	13.33	-	-	-%
Apr 05, 2024	NBC SECURITIES, INC.	unchanged	-	-1,000	1,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	664	8,613	9,641	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	new	-	30,417	30,417	0.01%
Mar 27, 2024	NOMURA HOLDINGS INC	added	4.95	24,905	265,919	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	29,190	29,190	-%
Mar 11, 2024	VANGUARD GROUP INC	added	13.22	12,193,500	76,278,700	-%
Mar 05, 2024	PBCay One RSC Ltd	new	-	95,684	95,684	0.02%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	360	10,479,000	13,204,400	-%

Are Funds Buying or Selling VERV?

Are funds buying VERV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VERV

No. of Funds

Unveiling Verve Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	6.81%	5,471,930	SC 13G/A
Jan 29, 2024	ark investment management llc	8.74%	7,025,116	SC 13G/A
Jan 29, 2024	blackrock inc.	5.6%	4,435,481	SC 13G
Jan 23, 2024	state street corp	4.81%	3,866,764	SC 13G/A
Dec 11, 2023	fmr llc	-	0	SC 13G/A
Dec 11, 2023	gv 2017, l.p.	7.6%	6,108,442	SC 13G/A
Feb 14, 2023	singer james r	8.1%	5e+06	SC 13G/A
Feb 14, 2023	casdin capital, llc	3.7%	2,290,571	SC 13G/A
Feb 13, 2023	arch venture fund x, l.p.	-	0	SC 13G/A
Feb 10, 2023	blackrock inc.	5.8%	3,594,074	SC 13G

Recent SEC filings of Verve Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	8-K	Current Report
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	8-K	Current Report
Feb 27, 2024	S-8	Employee Benefits Plan
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading
Feb 16, 2024	4	Insider Trading

Peers (Alternatives to Verve Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.0B	6.8B	-2.93%	-28.56%	-8.27	5.69	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-2.14%	-28.32%	-41.48	9.99	76.23%	61.08%
BMRN	17.0B	2.4B	5.64%	-9.07%	101.38	7.03	15.42%	18.43%
INCY	11.9B	3.7B	-9.46%	-28.45%	19.84	3.21	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-16.55%	-42.15%	-10.83	14.44	425.83%	18.94%
BBIO	4.4B	-	-12.14%	49.76%	-6.72	60.35	54.84%	-34.79%
AXSM	3.1B	270.6M	-14.48%	-8.88%	-13.02	11.51	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.72%	-14.74%	-45.89	3.87	40.45%	71.62%
ARWR	2.8B	240.7M	-18.65%	-25.84%	-9.43	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.41%	-11.48%	25.32	4.54	85.90%	-14.05%
NVAX	544.4M	983.7M	-21.26%	-56.58%	-1	0.55	-50.36%	17.16%
CRBP	382.8M	881.7K	-14.69%	262.26%	-8.58	466.16	-77.61%	-5.33%
INO	238.4M	4.9M	-4.49%	-3.41%	-1.76	48.98	-54.97%	51.71%
IBIO	6.2M	2.1M	67.92%	36.92%	-0.23	2.14	-13.45%	66.37%

Verve Therapeutics, Inc. News

Latest updates

Verve Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4
Revenue	65.0%	5,144,000	3,117,000	2,093,000	1,404,000	1,166,500	929,000	-
Operating Expenses	6.6%	59,092,000	55,451,000	60,676,000	59,663,000	48,722,000	44,789,000	32,540,000
S&GA Expenses	5.1%	12,281,000	11,686,000	13,416,000	12,553,000	11,438,500	9,592,000	6,601,000
R&D Expenses	7.0%	46,811,000	43,765,000	47,260,000	47,110,000	37,283,500	35,197,000	25,939,000
EBITDA Margin	19.8%	-15.60	-19.44	-28.18	-41.72	-79.61	-	-
Income Taxes	-52.2%	32,000	67,000	200,000	-	53,000	-	-
Earnings Before Taxes	-5.8%	-48,320,000	-45,691,000	-53,807,000	-	-41,032,000	-45,190,000	-
EBT Margin	19.5%	-16.06	-19.96	-28.93	-42.64	-81.06	-	-
Net Income	-5.7%	-48,352,000	-45,758,000	-53,983,000	-51,975,000	-41,085,000	-45,190,000	-31,337,000
Net Income Margin	17.9%	-17.02	-20.72	-35.35	-48.57	-81.09	-	-
Free Cashflow	-233.0%	-42,865,000	-12,872,000	-50,624,000	-52,471,000	-37,860,000	-31,812,000	-29,024,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	22.9%	753	612	589	634	679	673	324	349	384	411	427	78.00
Current Assets	28.0%	638	498	473	518	563	562	299	329	367	394	420	74.00
Cash Equivalents	163.1%	206	78.00	70.00	84.00	115	277	73.00	91.00	70.00	148	387	9.00
Net PPE	8.2%	23.00	21.00	21.00	21.00	19.00	15.00	12.00	11.00	7.00	7.00	6.00	4.00
Liabilities	0.8%	153	152	124	125	128	125	28.00	18.00	27.00	26.00	21.00	17.00
Current Liabilities	7.0%	37.00	35.00	33.00	34.00	35.00	29.00	26.00	15.00	22.00	20.00	9.00	7.00
Shareholder's Equity	30.2%	600	460	465	509	551	548	296	331	357	385	405	-63.91
Retained Earnings	-9.7%	-544	-495	-450	-396	-344	-303	-257	-217	-186	-155	-132	-66.54
Additional Paid-In Capital	19.5%	1,143	957	916	906	896	852	555	549	544	540	538	3.00
Shares Outstanding	28.6%	82.00	64.00	62.00	62.00	62.00	57.00	49.00	49.00	27.00	20.00	8.00	2.00
Float	-	-	-	940	-	-	-	557,600	-	-	-	2,185	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-244.4%	-40,680	-11,811	-47,962	-49,096	-32,892	-29,175	-26,758	-33,507	-28,043	-21,355	-13,341	-15,141	-14,975	-6,324	-	-
Share Based Compensation	4.9%	9,254	8,825	9,013	8,024	6,704	5,920	5,650	4,203	2,758	2,293	1,351	670	442	213	-	-
Cashflow From Investing	24.9%	-8,893	-11,834	33,025	15,392	-168,313	-55,516	7,782	60,092	-56,985	-212,316	18,489	11,714	11,887	-2,718	-	-
Cashflow From Financing	455.7%	177,383	31,923	1,233	2,038	39,598	288,408	445	505	1,224	-867	282,901	93,831	8.00	-	-	-

VERV Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Collaborations revenue	$ 11,758	$ 1,941	$ 0
Operating expenses:
Research and development	184,946	130,095	68,202
General and administrative	49,936	37,533	18,865
Total operating expenses	234,882	167,628	87,067
Loss from operations	(223,124)	(165,687)	(87,067)
Other income (expense):
Change in fair value of antidilution rights liability	0	0	(25,574)
Change in fair value of success payment liability	165	1,486	(7,815)
Interest and other income, net	23,166	6,867	142
Total other income (expense), net	23,331	8,353	(33,247)
Loss before provision for income taxes	(199,793)	(157,334)	(120,314)
Provision for income taxes	(275)	(53)	0
Net loss	$ (200,068)	$ (157,387)	$ (120,314)
Net loss per common share, basic	$ (3.12)	$ (2.91)	$ (4.48)
Net loss per common share, diluted	$ (3.12)	$ (2.91)	$ (4.48)
Weighted-average common shares used in net loss, basic	64,175,137	54,023,653	26,872,036
Weighted-average common shares used in net loss, diluted	64,175,137	54,023,653	26,872,036
Comprehensive Loss:
Net Income (Loss)	$ (200,068)	$ (157,387)	$ (120,314)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	966	(466)	(236)
Comprehensive loss	$ (199,102)	$ (157,853)	$ (120,550)

VERV Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 206,180	$ 115,412
Marketable securities	417,770	439,396
Collaboration receivable	5,897	1,012
Prepaid expenses and other current assets	8,102	7,339
Total current assets	637,949	563,159
Property and equipment, net	22,505	18,778
Restricted cash	4,774	4,824
Operating lease right-of-use assets	85,295	91,877
Other long term assets	2,165	585
Total assets	752,688	679,223
Current liabilities:
Accounts payable	6,636	2,424
Accrued expenses	20,178	20,767
Operating lease obligations, current portion	10,192	11,904
Total current liabilities	37,006	35,095
Long-term lease liability	64,715	70,014
Deferred revenue, non-current	48,556	20,014
Success payment liability	2,720	2,885
Other long term liabilities	189	283
Total liabilities	153,186	128,291
Commitments and contingencies (See Note 7 and 8)
Stockholders' equtiy
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized, 81,969,693 and 61,730,816 shares issued and outstanding at December 31, 2023 and 2022, respectively	82	62
Additional paid-in capital	1,143,453	895,801
Accumulated other comprehensive loss	272	(694)
Accumulated deficit	(544,305)	(344,237)
Total stockholders' equity	599,502	550,932
Total liabilities and stockholders' equity	$ 752,688	$ 679,223

About Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Sekar Kathiresan M.D.
WEBSITE	vervetx.com
INDUSTRY	Biotechnology
EMPLOYEES	204

Verve Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Verve Therapeutics, Inc.? What does VERV stand for in stocks?

VERV is the stock ticker symbol of Verve Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Verve Therapeutics, Inc. (VERV)?

As of Thu Apr 18 2024, market cap of Verve Therapeutics, Inc. is 545.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VERV stock?

You can check VERV's fair value in chart for subscribers.

What is the fair value of VERV stock?

You can check VERV's fair value in chart for subscribers. The fair value of Verve Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Verve Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VERV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Verve Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VERV is over valued or under valued. Whether Verve Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Verve Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERV.

What is Verve Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, VERV's PE ratio (Price to Earnings) is -2.73 and Price to Sales (PS) ratio is 46.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VERV PE ratio will change depending on the future growth rate expectations of investors.